Literature DB >> 26637197

Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases.

Arne Warth1, Sandrina Körner2, Roland Penzel3, Thomas Muley4, Hendrik Dienemann5, Peter Schirmacher3, Magnus von Knebel-Doeberitz2, Wilko Weichert3,6,7, Matthias Kloor2,8,9.   

Abstract

A major molecular pathway of genetic instability in cancer is DNA mismatch repair deficiency, leading to accumulation of numerous mutations at repetitive DNA sequence stretches (microsatellites), known as high-level microsatellite instability (MSI-H). In colorectal cancer, MSI-H tumors show a clinical behavior different from microsatellite-stable (MSS) tumors. Data about the prevalence of MSI among non-small cell lung cancer (NSCLC) are conflicting, and clinical relevance of MSI is largely unknown. We analyzed a series of 480 pulmonary adenocarcinomas (ADC) for MSI using a sensitive mononucleotide marker panel (BAT25, BAT26, and CAT25). Positive cases were further analyzed by immunohistochemical staining for DNA mismatch repair proteins. Results were correlated with clinicopathological variables. MSI-H was detected in 4/480 (0.8 %) cases. In none of these, a background of Lynch syndrome was found. Three of the patients developed a metachronous carcinoma (esophagus, pancreas, and kidney). All MSI-H cases were stage I and occurred in smokers/ex-smokers. Mutations were found in EGFR (n = 2), KRAS (n = 1), or BRAF (n = 1). MSI-H neoplasms had a higher proliferative activity (38.7 %) than MSS neoplasms (28.3 %). Mean overall survival for MSS and MSI-H cases was 64.8 (CI 60.4-69.1) and 47.1 (CI 21-73.2) months, respectively. When specific mononucleotide marker panels are applied, the MSI-H phenotype is rare and predominantly found in early stage ADC of smokers. However, the frequency of MSI-H is in the range of other relevant molecular alterations. In the era of precision therapy, associations with distinct clinicopathological variables merit further investigation.

Entities:  

Keywords:  Adenocarcinoma; Lung cancer; Microsatellite instability; Mismatch repair

Mesh:

Year:  2015        PMID: 26637197     DOI: 10.1007/s00428-015-1892-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  47 in total

1.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Authors:  Arne Warth; Thomas Muley; Michael Meister; Albrecht Stenzinger; Michael Thomas; Peter Schirmacher; Philipp A Schnabel; Jan Budczies; Hans Hoffmann; Wilko Weichert
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

2.  Microsatellite alterations in plasma DNA of small cell lung cancer patients.

Authors:  X Q Chen; M Stroun; J L Magnenat; L P Nicod; A M Kurt; J Lyautey; C Lederrey; P Anker
Journal:  Nat Med       Date:  1996-09       Impact factor: 53.440

Review 3.  Chemotherapy of MMR-deficient colorectal cancer.

Authors:  N Devaud; S Gallinger
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

4.  EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

Authors:  Arne Warth; Roland Penzel; Heike Lindenmaier; Regine Brandt; Albrecht Stenzinger; Esther Herpel; Benjamin Goeppert; Michael Thomas; Felix J F Herth; Hendrik Dienemann; Philipp A Schnabel; Peter Schirmacher; Hans Hoffmann; Thomas Muley; Wilko Weichert
Journal:  Eur Respir J       Date:  2013-08-29       Impact factor: 16.671

5.  Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers.

Authors:  Vanessa Deschoolmeester; Marc Baay; Wim Wuyts; Eric Van Marck; Nancy Van Damme; Peter Vermeulen; Krzysztof Lukaszuk; Filip Lardon; Jan B Vermorken
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

6.  Genetic instability in lung cancer: concurrent analysis of chromosomal, mini- and microsatellite instability and loss of heterozygosity.

Authors:  H Ninomiya; K Nomura; Y Satoh; S Okumura; K Nakagawa; M Fujiwara; E Tsuchiya; Y Ishikawa
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

7.  Allelic imbalance and instability of microsatellite loci on chromosome 1p in human non-small-cell lung cancer.

Authors:  A V Gasparian; K K Laktionov; M S Belialova; N A Pirogova; A G Tatosyan; I B Zborovskaya
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640

8.  "Unique trend" and "contradictory trend" in discrimination of primary synchronous lung cancer and metastatic lung cancer.

Authors:  Cheng Shen; Huan Xu; Lunxu Liu; Yubin Zhou; Dali Chen; Heng Du; Zhaojie Han; Guowei Che
Journal:  BMC Cancer       Date:  2013-10-09       Impact factor: 4.430

9.  Mutational landscape and significance across 12 major cancer types.

Authors:  Cyriac Kandoth; Michael D McLellan; Fabio Vandin; Kai Ye; Beifang Niu; Charles Lu; Mingchao Xie; Qunyuan Zhang; Joshua F McMichael; Matthew A Wyczalkowski; Mark D M Leiserson; Christopher A Miller; John S Welch; Matthew J Walter; Michael C Wendl; Timothy J Ley; Richard K Wilson; Benjamin J Raphael; Li Ding
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

10.  Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study.

Authors:  Karolina H Czarnecka; Monika Migdalska-Sęk; Adam Antczak; Dorota Pastuszak-Lewandoska; Jacek Kordiak; Ewa Nawrot; Daria Domańska; Dorota Kaleta; Paweł Górski; Ewa Barbara Brzeziańska
Journal:  Mol Biol Rep       Date:  2013-10-04       Impact factor: 2.316

View more
  26 in total

Review 1.  Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?

Authors:  Matthew Evans; Brendan O'Sullivan; Matthew Smith; Philippe Taniere
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.

Authors:  Frédérique Penault-Llorca; Nina Radosevic-Robin
Journal:  Transl Lung Cancer Res       Date:  2018-12

3.  Long-Lasting Response to Nivolumab for a Patient With Lynch Syndrome-Associated Lung Adenocarcinoma.

Authors:  Keita Masuzawa; Takanori Asakura; Shinnosuke Ikemura; Hiroyuki Yasuda; Ichiro Kawada; Sosuke Takaoka; Yuichiro Hayashi; Takeshi Nakajima; Masami Arai; Koichi Fukunaga; Kenzo Soejima
Journal:  JCO Precis Oncol       Date:  2020-02-14

Review 4.  Moving pan-cancer studies from basic research toward the clinic.

Authors:  Feng Chen; Michael C Wendl; Matthew A Wyczalkowski; Matthew H Bailey; Yize Li; Li Ding
Journal:  Nat Cancer       Date:  2021-09-16

5.  Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.

Authors:  Di Huang; Fan Zhang; Haitao Tao; Sujie Zhang; Junxun Ma; Jinliang Wang; Zhefeng Liu; Pengfei Cui; Shixue Chen; Ziwei Huang; Zhaozhen Wu; Lei Zhao; Yi Hu
Journal:  Target Oncol       Date:  2020-02       Impact factor: 4.864

6.  Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.

Authors:  Christina Therkildsen; Steen Ladelund; Lars Smith-Hansen; Lars Joachim Lindberg; Mef Nilbert
Journal:  Br J Cancer       Date:  2017-10-24       Impact factor: 7.640

7.  New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.

Authors:  Takahiro Nakagomi; Taichiro Goto; Yosuke Hirotsu; Daichi Shikata; Yujiro Yokoyama; Rumi Higuchi; Kenji Amemiya; Kenichiro Okimoto; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Oncotarget       Date:  2018-01-31

Review 8.  Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.

Authors:  Boris Duchemann; Jordi Remon; Marie Naigeon; Lydie Cassard; Jean Mehdi Jouniaux; Lisa Boselli; Jonathan Grivel; Edouard Auclin; Aude Desnoyer; Benjamin Besse; Nathalie Chaput
Journal:  Transl Lung Cancer Res       Date:  2021-06

9.  Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.

Authors:  Christoph Fraune; Ronald Simon; Claudia Hube-Magg; Georgia Makrypidi-Fraune; Martina Kluth; Franziska Büscheck; Tania Amin; Fabrice Viol; Wilfrid Fehrle; David Dum; Doris Höflmayer; Eike Burandt; Till Sebastian Clauditz; Daniel Perez; Jakob Izbicki; Waldemar Wilczak; Guido Sauter; Stefan Steurer; Jörg Schrader
Journal:  Endocr Pathol       Date:  2020-06       Impact factor: 3.943

Review 10.  Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach.

Authors:  Taichiro Goto; Yosuke Hirotsu; Kenji Amemiya; Hitoshi Mochizuki; Masao Omata
Journal:  Cancers (Basel)       Date:  2018-06-22       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.